ArticleJournal of clinical biochemistry and nutrition2012
An immunosuppressive subtype of neutrophils identified in patients with hepatocellular carcinoma.
Article in Journal of clinical biochemistry and nutrition, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 43 citations in OpenAlex.
- Human immunosuppressive neutrophils: recent answers to old and new questions.The EMBO journal · 2026Review
- Neutrophil Heterogeneity in Airway Inflammatory Diseases.Inflammation · 2025Review
- Article
- Gamma-Glutamyl Transpeptidase to Neutrophil Ratio as Prognostic Indicator for Hepatocellular Carcinoma Patients Post-Curative Resection.Journal of hepatocellular carcinoma · 2024Article
- Bronchoalveolar cytokine profile differentiates Pulmonary Langerhans cell histiocytosis patients from other smoking-related interstitial lung diseases.Respiratory research · 2023Article
- Immunoregulatory functions of mature CD10Frontiers in medicine · 2022Article
- Inflammatory processes in the liver: divergent roles in homeostasis and pathology.Cellular & molecular immunology · 2021Review
- Uncovering the multifaceted roles played by neutrophils in allogeneic hematopoietic stem cell transplantation.Cellular & molecular immunology · 2021Review
- The Roles of Neutrophils in the Pathogenesis of Liver Diseases.Frontiers in immunology · 2021Review
- Breast Cancer Cell-Neutrophil Interactions Enhance Neutrophil Survival and Pro-Tumorigenic Activities.Cancers · 2020Article
- Future of immune checkpoint inhibitors: focus on tumor immune microenvironment.Annals of translational medicine · 2020Review
- Neutrophils in the Tumor Microenvironment.Advances in experimental medicine and biology · 2020Review
- Article
- Tumor-Associated Neutrophils in Cancer: Going Pro.Cancers · 2019Review
- Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression.World journal of gastroenterology · 2018Review
- Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma.Oncotarget · 2017Article
- Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients.Oncotarget · 2016Article
- Neutrophil-derived chemokines on the road to immunity.Seminars in immunology · 2016Review
- The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2015Article
- Chemokines and their receptors play important roles in the development of hepatocellular carcinoma.World journal of hepatology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Functional disorders of various immune cells have been reported in hepatocellular carcinoma (HCC) patients. Recently, distinct subsets of neutrophils (polymorphonuclear leukocytes, PMN) have been identified in hosts with enhanced or impaired cell-mediated immunity. In this study, therefore, plasma factors and PMN from HCC patients were immunobiologically investigated. Plasma neopterin and CCL17 levels were measured by ELISA in 95 HCC patients. Peripheral PMN were isolated from each HCC patient and tested for CCL2 or CCL3 production by ELISA and flow cytometry. The results showed elevated plasma neopterin levels in HCC patients, while CCL17 levels decreased in correlation with tumor size. PMN from HCC patients produced CCL2, while PMN from healthy subjects did not. Moreover, CCL2 production by PMN was significantly increased in proportion to tumor load. When HCC patients were divided into two groups based on CCL2 produced by PMN, the survival rate of the CCL2 high group was significantly lower than that for other patients. While CCL3 production by PMN was also significantly increased in HCC patients, their CCL3 production did not correlate with tumor load and survival. The CCL2/CCL3 ratio in culture fluids of each PMN was also increased in proportion to tumor size. These results suggest that cell-mediated immunity may be impaired in advanced HCC patients. Moreover, distinct PMN subsets may exist in the peripheral blood of HCC patients. These PMN subsets, especially CCL2-producing PMN, may be involved in tumor extension and the survival outcomes for HCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.